The Role of T-Cells in Lymphomas and Leukemias

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 31 May 2025 | Viewed by 685

Special Issue Editor


E-Mail
Guest Editor
Don Brown Professor of Immunotherapy Professor, Department of Medicine, Microbiology and Immunology Indiana University School of Medicine and Cancer Center, 975 W. Walnut St., IB554A, Indianapolis, IN 46202, USA
Interests: T cells; regulatory T cells; leukemia; lymphoma; hematological malignancies; chimeric antigen receptor; CAR T cells; tumor microenvironment; tumor-infiltrating T cells; TCR; adoptive T cell therapy; TCR-engineered T cells

Special Issue Information

Dear Colleagues,

We are delighted to announce a Special Issue of Cells, focusing on "The Role of T-cells in Lymphomas and Leukemias". This Special Issue aims to highlight the latest research and advancements in understanding the critical functions of T cells in the pathogenesis, progression, and treatment of lymphomas and leukemias.

T cells play a pivotal role in the immune response against malignancies. Their involvement in both protective immunity and disease pathology offers a dual perspective that is crucial for developing targeted therapies and improving patient outcomes. This Special Issue seeks to compile cutting-edge research articles and reviews that explore various aspects of T cell biology in the context of these hematologic cancers.

Topics of interest include, but are not limited to the following:

  • Mechanisms of T cell activation and regulation in lymphomas and leukemias;
  • The role of T cell subtypes in tumor immunity and the microenvironment;
  • T cell-based immunotherapies and their clinical applications;
  • Genetic and epigenetic modifications affecting T cell function in hematologic malignancies;
  • The impact of the tumor microenvironment on T cell responses.

We invite researchers, clinicians, and scholars to contribute their original research articles and  comprehensive reviews to this Special Issue. Submissions will undergo a rigorous peer-review process to ensure the publication of high-quality and impactful scientific work.

We look forward to your valuable contributions that will drive forward our understanding of T cells in the context of lymphomas and leukemias. Together, we can pave the way for innovative therapies and improved patient care.

Dr. Huda Salman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • T cells
  • regulatory T cells
  • leukemia
  • lymphoma
  • hematological malignancies
  • chimeric antigen receptor
  • CAR T cells
  • tumor microenvironment
  • tumor-infiltrating T cells
  • TCR
  • adoptive T cell therapy
  • TCR-engineered T cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 4959 KiB  
Communication
Characterisation of Cytotoxicity-Related Receptors on γδ T Cells in Chronic Lymphocytic Leukaemia
by Michał Zarobkiewicz, Natalia Lehman, Izabela Morawska-Michalska, Adam Michalski, Wioleta Kowalska, Agata Szymańska, Waldemar Tomczak and Agnieszka Bojarska-Junak
Cells 2025, 14(6), 451; https://doi.org/10.3390/cells14060451 - 18 Mar 2025
Viewed by 355
Abstract
Chronic lymphocytic leukaemia (CLL) is a haematological malignancy primarily affecting older adults, characterised by the proliferation of functionally impaired B lymphocytes with abnormal expression of CD5, a typical T cell marker. The current study investigates the expression of cytotoxicity-related receptors (CD16, CD56, CD57, [...] Read more.
Chronic lymphocytic leukaemia (CLL) is a haematological malignancy primarily affecting older adults, characterised by the proliferation of functionally impaired B lymphocytes with abnormal expression of CD5, a typical T cell marker. The current study investigates the expression of cytotoxicity-related receptors (CD16, CD56, CD57, CD69) and a checkpoint (LAG-3) on γδ T cells in CLL patients. Sixty-nine treatment-naive CLL patients and fourteen healthy controls were recruited. Flow cytometry analysis revealed that the CLL patients had higher expressions of CD56 and LAG-3 and lower CD16 on their γδ T cells compared to the healthy controls. Subgroup analysis showed that ZAP-70-negative patients exhibited increased CD69, while CD38-negative patients showed higher CD16 expression. Additionally, CD16 expression was inversely correlated with serum LDH levels, a marker of disease progression. Bioinformatic analysis of the LAG-3 ligand mRNA in a CLL dataset indicated higher expression of HLA-DQA2 and HLA-DRB5 in patients with unmutated IGVH. Our findings highlight the altered expression of key cytotoxicity markers on γδ T cells in CLL, suggesting their potential role in disease progression and as a therapeutic target. In particular, the use of anti-LAG-3 antibodies seems promising. Full article
(This article belongs to the Special Issue The Role of T-Cells in Lymphomas and Leukemias)
Show Figures

Figure 1

Back to TopTop